William Blair Analysts Cut Earnings Estimates for Medtronic

Medtronic plc (NYSE:MDT) – Research analysts at William Blair decreased their Q3 2026 earnings per share (EPS) estimates for Medtronic in a report issued on Tuesday, November 19th. William Blair analyst M. Andrew now forecasts that the medical technology company will post earnings of $1.46 per share for the quarter, down from their prior estimate of $1.49. The consensus estimate for Medtronic’s current full-year earnings is $5.46 per share. William Blair also issued estimates for Medtronic’s Q4 2026 earnings at $1.68 EPS.

Medtronic (NYSE:MDT) last announced its quarterly earnings results on Tuesday, November 19th. The medical technology company reported $1.26 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.25 by $0.01. Medtronic had a return on equity of 13.79% and a net margin of 13.00%. The company had revenue of $8.40 billion during the quarter, compared to the consensus estimate of $8.27 billion. During the same period in the previous year, the company posted $1.25 earnings per share. Medtronic’s revenue for the quarter was up 5.2% on a year-over-year basis.

Several other research analysts also recently weighed in on MDT. Citigroup upped their target price on Medtronic from $85.00 to $92.00 and gave the stock a “neutral” rating in a research note on Tuesday, October 1st. Royal Bank of Canada raised Medtronic from a “sector perform” rating to an “outperform” rating and upped their target price for the stock from $98.00 to $105.00 in a research note on Thursday, October 10th. Piper Sandler upped their target price on Medtronic from $85.00 to $90.00 and gave the stock a “neutral” rating in a research note on Wednesday, August 21st. Evercore ISI upped their target price on Medtronic from $100.00 to $104.00 and gave the stock an “outperform” rating in a research note on Tuesday, October 1st. Finally, Oppenheimer upped their target price on Medtronic from $92.00 to $94.00 and gave the stock a “market perform” rating in a research note on Wednesday, August 21st. One equities research analyst has rated the stock with a sell rating, nine have given a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus target price of $95.19.

Medtronic Trading Up 0.7 %

Shares of NYSE:MDT opened at $84.71 on Friday. The company has a current ratio of 1.84, a quick ratio of 1.61 and a debt-to-equity ratio of 0.51. The company has a market capitalization of $108.63 billion, a PE ratio of 25.90, a PEG ratio of 2.42 and a beta of 0.84. The business has a 50 day moving average of $89.07 and a two-hundred day moving average of $84.84. Medtronic has a 12-month low of $75.96 and a 12-month high of $92.68.

Institutional Trading of Medtronic

Large investors have recently added to or reduced their stakes in the stock. Fortitude Family Office LLC acquired a new position in Medtronic during the 3rd quarter worth about $27,000. Darwin Wealth Management LLC acquired a new stake in Medtronic in the 3rd quarter valued at about $27,000. Highline Wealth Partners LLC acquired a new stake in Medtronic in the 3rd quarter valued at about $27,000. J. Stern & Co. LLP acquired a new stake in Medtronic in the 3rd quarter valued at about $30,000. Finally, Lynx Investment Advisory acquired a new stake in Medtronic in the 2nd quarter valued at about $28,000. 82.06% of the stock is currently owned by hedge funds and other institutional investors.

About Medtronic

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.